Ignite Creation Date:
2024-05-05 @ 10:24 PM
Last Modification Date:
2024-10-26 @ 10:18 AM
Study NCT ID:
NCT01100736
Status:
COMPLETED
Last Update Posted:
2015-07-21
First Post:
2010-03-30
Brief Title:
Role of Endothelin-A ETA and Endothelin-B ETB Receptors in the Vasodilatory Response to Endothelin-3 ET-3
Sponsor:
University of Edinburgh
Organization:
University of Edinburgh
Study Overview
Official Title:
Characterisation of the Role of ETA and ETB Receptors in Regulating Plasma ET-1 and the Vasodilator Response to ET-3 in Man
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Endothelin-1 ET-1 has been linked to a number of conditions including pulmonary arterial hypertension PAH ET-1 acts via 2 receptors ETA and ETB The ET-1 receptor blockers bosentan and sitaxsentan have been shown to be beneficial in patients with PAH Bosentan blocks both ETA and ETB receptors Sitaxsentan selectively blocks ETA receptors Theoretically selective ETA blockade may be associated with greater vasodilation and clearance of ET-1 by leaving the ETB receptor unblocked This has not been directly studied in humans
We aim to investigate the endothelial ETB-mediated vascular responses between bosentan and sitaxsentan by using a ETB selective agonist ET-3 We hypothesise that at clinically relevant doses
Bosentan will show evidence of ETB receptor blockade compared to sitaxsentan and placebo
These effects will be confirmed by 2 functional markers of ETB receptor antagonism plasma ET-1 a very sensitive but not necessarily clinically relevant marker and the forearm vasodilator response to ET-3
We aim to investigate the endothelial ETB-mediated vascular responses between bosentan and sitaxsentan by using a ETB selective agonist ET-3 We hypothesise that at clinically relevant doses
Bosentan will show evidence of ETB receptor blockade compared to sitaxsentan and placebo
These effects will be confirmed by 2 functional markers of ETB receptor antagonism plasma ET-1 a very sensitive but not necessarily clinically relevant marker and the forearm vasodilator response to ET-3
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 08S11021 | None | None | None |